{"entity":{"id":"exscientia","kind":"company","name":"Exscientia","aka":[],"tldr":"Exscientia was a British pioneer in designing drugs with artificial intelligence, including cancer drugs that reached early clinical trials. It has been folded into the US company Recursion.","summary":"Exscientia plc, founded in Oxford, was among the first companies to bring AI-designed small molecules into clinical trials, combining generative chemistry design with automated synthesis and patient-tissue functional screening. Its oncology pipeline included GTAEXS617, a CDK7 inhibitor developed with GT Apeiron, and EXS4318, a PKC-theta inhibitor partnered with Bristol Myers Squibb, together with a large discovery collaboration with Sanofi. The company combined with Recursion Pharmaceuticals in an all-stock transaction in 2024; the exscientia.ai domain now redirects to recursion.com and the former Exscientia programmes are reported within Recursion's pipeline. Deal value and completion date could not be confirmed from a fetched primary source because Recursion's investor relations pages blocked automated access. Recursion itself is already in the graph.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.exscientia.ai"},{"label":"Recursion website","url":"https://www.recursion.com/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Acquisition by Recursion is evidenced only by the domain redirect; the completion release (November 2024) and deal value were not fetched (ir.recursion.com returned 403 or timed out). Oncology programme details are from background knowledge and were not on fetched pages. Former ticker EXAI omitted."],"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.exscientia.ai","stage":"acquired","investors":[],"funding":[],"acquiredBy":"recursion"},"route":"/companies/exscientia/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}